Cardiovascular Disease Clinical Trial
Official title:
Addressing Social Determinants of Health During Clinical Care Visits to Promote Equitable Behavior Change and PREVENT Cardiovascular Disease
Verified date | April 2023 |
Source | Washington University School of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to test the feasibility of a novel, Health Information Technology behavior change tool in a single clinic setting. The PREVENT tool is the first electronic health record (EHR)-compatible tool that both tailors evidence-based behavior change strategies and incorporates community-level data specific to each patient into routine care. The central hypothesis is that PREVENT will improve patient's attitudes towards behavior change recommendations, increase adherence to recommended behavior change and improve cardiovascular health. Fifty adolescents will be randomized to intervention or wait-list, routine care control to assess the preliminary effectiveness of PREVENT. Qualitative and quantitative methods will be used among patients, parents and providers to examine barriers to current and future implementation of the PREVENT tool to inform adoption and maintenance.
Status | Completed |
Enrollment | 65 |
Est. completion date | February 14, 2022 |
Est. primary completion date | February 14, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 19 Years |
Eligibility | Inclusion Criteria: Patient Eligibility Criteria: - Adolescents 12 to 19 years - Prior diagnosis of pediatric cancer (diagnosed <21 years of age) - Not receiving active therapy for their cancer - Receiving care from the Pediatric Hematology/Oncology staff and physicians at St. Louis Children's Hospital or the St. Louis Children's Specialty Care Center (CSCC) - At risk for poor cardiovascular health (CVH) (BMI greater than or equal to 85th percentile) Provider Eligibility Criteria -All providers and staff (physicians, nurses, clinic staff, clinical research associates) in the Pediatric Hematology/Oncology program at St. Louis Children's Hospital and the CSCC Parent Eligibility Criteria -A parent or legal guardian of a study participant. The parent or legal guardian must have been present at the clinic visit in which the PREVENT tool was administered to the study participant. |
Country | Name | City | State |
---|---|---|---|
United States | Washington University School of Medicine | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine | National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Change in Minutes of Moderate Physical Activity Per Week (From Self Report) Survey | Physical activity will be measured using a triaxial accelerometer (Actigraph GT3X+, Actigraph of Ft. Walton Beach, FL). The participant will be instructed to wear the accelerometer on an elasticized belt, on the left mid-axillary line. The Actigraph is one of the most common accelerometers used for scientific purposes. Participants will be encouraged to wear the accelerometer 24-hours per day for at least 7-days, including 2 weekend days. Participants completed a brief Health Behavior & Attitudes Survey using questions from the International Physical Activity Questionnaire Mean changes from baseline and 3-month follow-up were calculated as the follow-up measure minus the baseline measure, averaged across the intervention groups.
Note: Actigraph measure was dropped due to university mail distribution delays during the remote work period of the COVID-19 pandemic. Self-reported change in minutes of physical activity became the primary outcome. |
At baseline and 3-months | |
Primary | Mean Change in Minutes of Vigorous Physical Activity Per Week (From Self Report) Survey | Physical activity will be measured using a triaxial accelerometer (Actigraph GT3X+, Actigraph of Ft. Walton Beach, FL). The participant will be instructed to wear the accelerometer on an elasticized belt, on the left mid-axillary line. The Actigraph is one of the most common accelerometers used for scientific purposes. Participants will be encouraged to wear the accelerometer 24-hours per day for at least 7-days, including 2 weekend days. Participants completed a brief Health Behavior & Attitudes Survey using questions from the International Physical Activity Questionnaire Mean changes from baseline and 3-month follow-up were calculated as the follow-up measure minus the baseline measure, averaged across the intervention groups.
Note: Actigraph measure was dropped due to university mail distribution delays during the remote work period of the COVID-19 pandemic. Self-reported change in minutes of physical activity became the primary outcome. |
At baseline and 3-months | |
Primary | Mean Change in Number of Food Intake Behaviors Met | Patient-reported food intake behaviors (fruit and vegetable intake, whole grains, sugar-sweetened beverages and snacking behaviors) are collected using a brief Health Behavior & Attitudes Survey. Responses are dichotomized into a binary yes (1)/no (0) score indicating whether or not the patient is meeting the food intake recommendation for each food group. The total number of food intake behaviors are scored on a 5 item scale (range 0-5), maximum improvement in number of behaviors=5. Mean changes from baseline and 3-month follow-up were calculated as the follow-up measure minus the baseline measure, averaged across the intervention groups. | At baseline and 3-months | |
Primary | Provider's Satisfaction of PREVENT Tool: Survey | A survey (24-questions) containing validated subscales assessed provider's satisfaction with the PREVENT tool on subscales assessing acceptability, feasibility, and appropriateness of the tool, and satisfaction with specific components of the tool. Items were scored on a 5-point Likert scale with a higher score indicating greater satisfaction. Subscales were summed to generate the average across all questions (range 1-5) and was reported as overall satisfaction. | 3-months | |
Primary | Fidelity of PREVENT Tool Implementation | Fidelity will be measured using direct observation of patient-provider interactions while using the PREVENT tool. A direct observation checklist will be used by the observer to determine the number of interactions with the PREVENT tool that were implemented as intended. | 0-3 months | |
Secondary | Provider's Motivation for Sustained Use of PREVENT Tool | A survey (8 questions) assessed provider's intent to change their behavior and continue using PREVENT. Questions were adapted from Legare's CPD Reaction Questionnaire and asked using a 5-point Likert scale (range 1-5). An average of all responses was calculated with a higher score indicating greater motivation for sustained use. | 3-months | |
Secondary | Maintenance of PREVENT Tool as Measured by Provider Perceptions of Feasibility of the Tool | Qualitative in-depth interview with providers who used the PREVENT tool. Qualitative content analysis methods were used to summarize key themes related to provider perceptions of the tool and ability to use the tool in routine clinical practice. | 3-months | |
Secondary | Maintenance of PREVENT Tool as Measured by Provider Perceptions of Ease of Use of the Tool | Qualitative in-depth interview with providers who used the PREVENT tool. Qualitative content analysis methods were used to summarize key themes related to provider perceptions of the tool and ability to use the tool in routine clinical practice. | 3-months | |
Secondary | Patient's Perceptions of Usability/Acceptability of PREVENT Tool | Semi-structured interviews with adolescent study participants (n=10). | 3-months | |
Secondary | Parent's Perceptions of Usability/Acceptability of PREVENT Tool | Semi-structured interviews with parents/guardians (n=10) of study participants. | 3-months | |
Secondary | Impact of PREVENT Tool on Mean Change in Patient's Body Mass Index (BMI) | Collected from patient's medical record. BMI z-score is a standardized calculation accounting age and sex using the Centers for Disease Control and Prevention Growth Charts. A z-score represents the standard deviation from the population mean. A z-score of zero represents the population mean. Mean change in BMI z-score was calculated by subtracting the baseline mean from the follow-up mean for each intervention group. A decrease in z-score is a favorable outcome. | At baseline and 3-months | |
Secondary | Impact of PREVENT Tool on Patient's Systolic and Diastolic Blood Pressure | Collected from patient's medical record. Blood pressure is measured in mmHg. The mean change was calculated by subtracting the baseline mean from the follow-up mean for each intervention group. | At baseline and 3-months | |
Secondary | Impact of PREVENT Tool on Patient's Cholesterol | Collected from patient's medical record | At baseline and 3-months | |
Secondary | Impact of PREVENT Tool on Patient's Fasting Blood Glucose | Collected from patient's medical record | At baseline and 3-months | |
Secondary | Impact of PREVENT Tool on Patient's Attitudes Toward Behavior Change | A survey (6-question) administered to patients will assess attitudes toward and readiness for behavior change. Questions are asked using a 5-point Likert scale (range: 0-5) with a higher score indicating more positive attitudes. | At baseline and 3-months | |
Secondary | Clinic-level Capacity for Sustainability as Measured by Provider Survey | The Clinical Sustainability Assessment Tool (CSAT) will assess clinic-level readiness and capacity for sustainability of the PREVENT tool. The CSAT tool will examine organization, financial, regulatory and political factors that may influence sustainability. 10 items scored on a 7-point scale, with higher scores indicating greater capacity for sustainment. The average of the 10 items is reported (range 1-7). | 3-months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02122198 -
Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
|
N/A | |
Completed |
NCT02502812 -
Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04216342 -
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03654313 -
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
|
Phase 1 | |
Completed |
NCT03646656 -
Heart Health Buddies: Peer Support to Decrease CVD Risk
|
N/A | |
Completed |
NCT02081066 -
Identification of CETP as a Marker of Atherosclerosis
|
N/A | |
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT06405880 -
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
|
N/A | |
Recruiting |
NCT03095261 -
Incentives in Cardiac Rehabilitation
|
N/A | |
Completed |
NCT02998918 -
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL
|
N/A | |
Completed |
NCT02711878 -
Healing Hearts and Mending Minds in Older Adults Living With HIV
|
N/A | |
Completed |
NCT02589769 -
Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons
|
N/A | |
Not yet recruiting |
NCT02578355 -
National Plaque Registry and Database
|
N/A | |
Completed |
NCT02868710 -
Individual Variability to Aerobic Exercise Training
|
N/A | |
Recruiting |
NCT02885792 -
Coronary Artery Disease in Patients Suffering From Schizophrenia
|
N/A | |
Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A | |
Completed |
NCT02640859 -
Investigation of Metabolic Risk in Korean Adults
|
||
Completed |
NCT02657382 -
Mental Stress Ischemia: Biofeedback Study
|
N/A | |
Completed |
NCT02272946 -
Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk
|
Phase 2 | |
Recruiting |
NCT02265250 -
Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
|